REPAY Holdings (RPAY) reported Q3 2025 results, missing both revenue and EPS estimates. The stock fell as revenue of $77.7M and EPS of $0.21 fell short of expectations.
Ambac Financial (soon Octave) beat Q3 2025 revenue estimates and posted a narrower loss, signaling progress in its strategic shift to a specialty insurance firm.
Mereo BioPharma (MREO) beat Q3 EPS estimates with a narrower loss. The clinical-stage company has cash into 2027 and key data for its lead drug expected soon.
ON24 (ONTF) beat Q3 2025 earnings and revenue estimates. The digital engagement platform also raised its full-year outlook and showed strong cash flow growth.
Theravance Biopharma (TBPH) reported Q3 2025 results, beating EPS estimates with a profit of $0.04. Revenue was slightly below forecasts. Lead drug YUPELRI achieved record sales.
Insight Molecular Dx (IMDX) stock fell 11.8% after missing Q3 2025 revenue and EPS estimates. The company remains focused on its FDA submission for the GraftAssureDx™ test.
DocGo's Q3 2025 results show a revenue miss but a narrower EPS loss. The stock fell as the company transitions away from migrant services, guiding for lower 2026 revenue.
Mobile Infrastructure (BEEP) reported mixed Q3 2025 results, missing revenue and earnings estimates. The company's net loss widened, but strategic growth in contract parking and a new $100M ABS provide a future roadmap.
Quest Resource (QRHC) posted mixed Q3 2025 results, beating revenue estimates but reporting a wider loss. The stock rose on the revenue beat and positive operational updates like debt reduction.
Identiv (INVE) Q3 2025 earnings: revenue slightly missed estimates, but the company beat on EPS with a smaller-than-expected loss, sending shares higher.
BCSF's Q3 2025 results show a mixed performance, with revenue missing estimates but core earnings covering its dividend. The market reaction was muted.
Natural Gas Services Group (NGS) reported mixed Q3 2025 results, beating earnings estimates but slightly missing on revenue. The company raised its full-year EBITDA guidance and highlighted a strong outlook for 2026.
Betting against the stock of a company like Nvidia -- with powerful financial performance and demand dynamics and a reasonable valuation -- is very risky.
As November 2025 unfolds, the Federal Reserve finds itself at a critical juncture, grappling with a complex dilemma: how to effectively manage liquidity in the financial system while simultaneously taming persistent inflation. This precarious balancing act is further complicated by a softening labor market, a lingering government shutdown that has
The relentless expansion of data centers, fueled by the explosive growth of artificial intelligence (AI) and the ever-increasing demand for cloud computing, is pushing global electricity grids to their limits and triggering a profound economic realignment. As of November 10, 2025, the digital infrastructure that underpins our modern world is
The recent, prolonged U.S. government shutdown has cast a long shadow over the nation's financial markets, creating an unprecedented data vacuum that has left investors, businesses, and policymakers navigating a fog of uncertainty. As federal agencies responsible for collecting and disseminating vital economic statistics ceased or drastically scaled back
The financial world is holding its breath as crucial US inflation data, previously delayed by a protracted government shutdown, finally sees the light of day. This long-awaited information, particularly the September Consumer Price Index (CPI) and Personal Consumption Expenditures (PCE) price index, is providing the Federal Reserve, businesses, and consumers
Vehicle systems manufacturer Commercial Vehicle Group (NASDAQ:CVGI) fell short of the markets revenue expectations in Q3 CY2025, with sales falling 11.2% year on year to $152.5 million. The company’s full-year revenue guidance of $645 million at the midpoint came in 1.6% below analysts’ estimates. Its non-GAAP loss of $0.14 per share was 16.7% below analysts’ consensus estimates.
